[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112019023246A8 - melhorias farmacocinéticas de quelatos bifuncionais e usos dos mesmos - Google Patents

melhorias farmacocinéticas de quelatos bifuncionais e usos dos mesmos

Info

Publication number
BR112019023246A8
BR112019023246A8 BR112019023246A BR112019023246A BR112019023246A8 BR 112019023246 A8 BR112019023246 A8 BR 112019023246A8 BR 112019023246 A BR112019023246 A BR 112019023246A BR 112019023246 A BR112019023246 A BR 112019023246A BR 112019023246 A8 BR112019023246 A8 BR 112019023246A8
Authority
BR
Brazil
Prior art keywords
bifunctional chelates
pharmacokinetic
pharmacokinetic improvements
chelates
bifunctional
Prior art date
Application number
BR112019023246A
Other languages
English (en)
Other versions
BR112019023246A2 (pt
BR112019023246B1 (pt
Inventor
Darwish Alla
Steven Burak Eric
Fitzmaurice Valliant John
Wayne Simms Ryan
James Mahoney Stuart
Original Assignee
Centre For Probe Dev And Commercialization
Steven Burak Eric
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre For Probe Dev And Commercialization, Steven Burak Eric, Fusion Pharmaceuticals Inc filed Critical Centre For Probe Dev And Commercialization
Publication of BR112019023246A2 publication Critical patent/BR112019023246A2/pt
Publication of BR112019023246A8 publication Critical patent/BR112019023246A8/pt
Publication of BR112019023246B1 publication Critical patent/BR112019023246B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção refere-se a conjugados incluindo uma fração quelante de um complexo metálico do mesmo e uma fração terapêutica ou de direcionamento, métodos para produção dos mesmos, e usos dos mesmos.
BR112019023246-0A 2017-05-05 2018-05-04 Compostos compreendendo uma fração quelante, métodos para produção dos mesmos e usos dos mesmos BR112019023246B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502260P 2017-05-05 2017-05-05
US62/502,260 2017-05-05
PCT/US2018/031228 WO2018204869A1 (en) 2017-05-05 2018-05-04 Pharmacokinetic enhancements of bifunctional chelates and uses thereof

Publications (3)

Publication Number Publication Date
BR112019023246A2 BR112019023246A2 (pt) 2020-05-19
BR112019023246A8 true BR112019023246A8 (pt) 2021-02-23
BR112019023246B1 BR112019023246B1 (pt) 2023-11-14

Family

ID=64016761

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019023246-0A BR112019023246B1 (pt) 2017-05-05 2018-05-04 Compostos compreendendo uma fração quelante, métodos para produção dos mesmos e usos dos mesmos

Country Status (14)

Country Link
US (2) US11191854B2 (pt)
EP (1) EP3619191A4 (pt)
JP (2) JP2020518673A (pt)
KR (1) KR102612882B1 (pt)
CN (2) CN111263747B (pt)
AU (2) AU2018261888B2 (pt)
BR (1) BR112019023246B1 (pt)
CA (1) CA3062553C (pt)
CL (1) CL2019003168A1 (pt)
EA (1) EA201992595A1 (pt)
MA (1) MA48861A (pt)
RU (1) RU2019139432A (pt)
WO (1) WO2018204869A1 (pt)
ZA (1) ZA201908071B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758636B2 (en) * 2013-11-12 2020-09-01 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
US11433148B2 (en) 2017-05-05 2022-09-06 Centre For Probe Development And Commercialization IGF-1R monoclonal antibodies and uses thereof
RU2019139432A (ru) 2017-05-05 2021-06-07 Сентр фор Проуб Девелопмент энд Коммерсиализэйшн Фармакокинетическая оптимизация бифункциональных хелатов и их применение
US20210236664A1 (en) * 2018-04-25 2021-08-05 The Johns Hopkins University Alpha particle formulations for treatment of solid tumors
CA3098492A1 (en) * 2018-04-27 2019-12-19 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
MA54399A (fr) * 2018-12-03 2021-10-13 Fusion Pharmaceuticals Inc Radioimmunoconjugués et polythérapie à base d'inhibiteur de point de contrôle
MX2022008605A (es) * 2020-01-10 2022-08-11 Fusion Pharmaceuticals Inc Quelatos macrociclicos y sus usos.
IL294589A (en) * 2020-01-10 2022-09-01 Fusion Pharmaceuticals Inc Prolonged immunotherapy
MX2022011635A (es) * 2020-03-23 2022-10-13 Fusion Pharmaceuticals Inc Radioinmunoconjugados dirigidos a fgfr3 y usos de estos.
KR102362962B1 (ko) * 2020-06-12 2022-02-16 (주)미래바이오팜 신규한 화합물 및 이를 함유하는 신경 손상, 신경 질환, 또는 발달 장애에 대한 신경세포의 증식 촉진, 분화, 및/또는 재생을 통한 치료 또는 예방용 약제학적 조성물
US20230296612A1 (en) * 2020-07-29 2023-09-21 Chugai Seiyaku Kabushiki Kaisha Method for measuring pharmacokinetics of agent labeled with non-radioactive substance
TW202304532A (zh) * 2021-03-23 2023-02-01 加拿大商融合製藥公司 治療癌症之方法
US20240299596A1 (en) * 2021-06-17 2024-09-12 Mayo Foundation For Medical Education And Research Methods and materials for combining biologics with multiple chelators
WO2023164777A1 (en) * 2022-03-04 2023-09-07 Fusion Pharmaceuticals Inc. Gucy2c-targeted radiopharmaceuticals and use thereof
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2024138060A2 (en) * 2022-12-21 2024-06-27 Mayo Foundation For Medical Education And Research Methods and materials for combining biologics with multiple chelators

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175343A (en) 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
DE3713842A1 (de) * 1987-04-22 1988-11-17 Schering Ag Substituierte cyclische komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US4889931A (en) 1988-09-27 1989-12-26 Salutar, Inc. Manganese (II) chelate manufacture
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0382583B1 (en) 1989-02-10 1996-01-17 Celltech Therapeutics Limited Aza macrocycles and processes for their preparation
US5053503A (en) 1989-02-17 1991-10-01 Centocor Chelating agents
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US6274713B1 (en) 1989-04-07 2001-08-14 Salutar, Inc. Polychelants
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
KR920000335A (ko) 1990-06-18 1992-01-29 리챠드 지. 워터맨 영상제로서 거대환상 아미노포스폰산 착체의 용도
US5386011A (en) 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
JPH07507804A (ja) 1992-06-09 1995-08-31 ネオルックス　コーポレーション 予備標的化方法及び化合物
US5358704A (en) 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents
GB9504922D0 (en) 1995-03-10 1995-04-26 Nycomed As Process
EP0970126B1 (en) 1997-04-14 2001-04-18 Micromet AG Novel method for the production of antihuman antigen receptors and uses thereof
IT1291624B1 (it) 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
IT1304501B1 (it) 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
EP1191948A2 (en) 1999-06-11 2002-04-03 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
DE10002939C1 (de) 2000-01-13 2001-09-20 Schering Ag Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln
US20020052354A1 (en) 2000-01-27 2002-05-02 Schering Ag Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
US6264966B1 (en) 2000-02-22 2001-07-24 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
WO2002024235A2 (en) 2000-05-12 2002-03-28 University Hospital Prochelators of radiometal labeled molecules
WO2002062398A2 (en) 2001-01-08 2002-08-15 Neorx Corporation Radioactively labelled conjugates of phosphonates
DE10135356C1 (de) 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
WO2004013161A2 (en) 2002-08-06 2004-02-12 Epix Pharmaceuticals, Inc. Peptide aggregates
DE10250870A1 (de) 2002-10-31 2004-05-13 Switch Biotech Ag Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung
US20060235296A1 (en) 2003-02-13 2006-10-19 Bracco Imaging S.P.A. Contrast enhanced x-ray phase imaging
NZ542371A (en) * 2003-03-19 2008-10-31 Universitatsspital Basel Radiolabeled conjugates based on substance P and the uses thereof
CA2526760A1 (en) 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
JP4262545B2 (ja) 2003-07-09 2009-05-13 三菱電機株式会社 カスコード接続回路及びその集積回路
DE602004025592D1 (de) 2003-09-12 2010-04-01 Life Technologies Corp Anwendungen des Resonanzenergietransfers zwischen Terbium und GFP
ATE516011T1 (de) 2003-12-19 2011-07-15 Schering Corp Pharmazeutische zusammensetzungen eines a2a rezeptorantagonisten
WO2005079803A1 (en) 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
WO2006015318A2 (en) 2004-07-30 2006-02-09 Biogen Idec Inc. Antibody conjugated to a drug moiety via a poptidic linker
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20060222595A1 (en) 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
WO2007009637A2 (de) 2005-07-15 2007-01-25 Bayer Schering Pharma Aktiengesellschaft Deren verwendung als kontrastmittel zur anwendung in der nmr-, rontgen- und radiodiagnostik sowie in der radiotheraphie
US7618957B2 (en) 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use
US20100226884A1 (en) * 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
US20080058636A1 (en) 2005-12-29 2008-03-06 Epix Pharmaceuticals, Inc. Methods of myocardial imaging
KR20080103562A (ko) 2006-03-15 2008-11-27 말린크로트, 인코포레이티드 치환된 방향족 잔기 및 그의 유도체를 갖는 킬레이팅 컨쥬게이트
US7777029B2 (en) 2006-05-02 2010-08-17 San Diego State University (Sdsu) Foundation Bifunctional chelators for sequestering lanthanides
US20080213811A1 (en) 2006-08-11 2008-09-04 Invitrogen Corporation Sensor proteins and assay methods
US8691761B2 (en) * 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
GB0624587D0 (en) 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
CN101626787A (zh) * 2007-01-19 2010-01-13 马林克罗特公司 诊断的和治疗的环氧合酶-2结合配体
WO2008134289A2 (en) 2007-04-26 2008-11-06 Mallinckrodt Inc. High relaxivity coordinatively unsaturated lanthanide complexes
JP2010537931A (ja) 2007-08-27 2010-12-09 マリンクロッド・インコーポレイテッド ナノ濾過および逆相クロマトグラフィーによる水溶性化合物からのシリカの除去
CA2697612A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
DE102008045937B4 (de) 2008-04-11 2017-01-26 Johannes-Gutenberg-Universität Mainz Radiopharmakon aus einem Metallion und einem Markierungsvorläufer und Verwendung des Radiopharmakons
US8546531B2 (en) 2008-07-16 2013-10-01 The General Hospital Corporation Methods and reagents for preparing multifunctional probes
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
US20110319339A1 (en) 2008-11-06 2011-12-29 Luisa Bracci Neurotensin-derived branched peptides and uses thereof
WO2010088527A2 (en) 2009-01-30 2010-08-05 Mayo Foundation For Medical Education And Research Peptides and nanoparticles for therapeutic and diagnostic applications
US20120116074A1 (en) 2009-03-19 2012-05-10 Thomas Gerard Cullen Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid and precursors thereof
US20120107248A1 (en) 2009-07-08 2012-05-03 Mayo Foundation For Medical Education And Research Imaging gastrointestinal volumes and motility
WO2011079315A1 (en) 2009-12-23 2011-06-30 The Scripps Research Institute Tyrosine bioconjugation through aqueous ene-like reactions
EP2525820B1 (en) 2010-01-19 2016-05-11 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
EP2397466B1 (en) * 2010-06-15 2012-11-28 Centre National De La Recherche Scientifique CNRS X-ray and gamma-photon activatable organic compounds, their preparation and their uses
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US12097269B2 (en) 2010-10-27 2024-09-24 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
EP2673297A2 (en) 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
US8685916B2 (en) 2011-03-09 2014-04-01 Signature Therapeutics, Inc. Opioid prodrugs with heterocyclic linkers
DK2721045T3 (en) 2011-06-20 2017-07-24 Radiomedix Inc COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS
FR2976825B1 (fr) 2011-06-22 2014-02-21 Total Sa Nanotraceurs pour le marquage d'eaux d'injection de champs petroliers
EP2604281B1 (en) 2011-12-14 2014-07-30 Centre National de la Recherche Scientifique (CNRS) Clicked somatostatin conjugated analogs for biological applications
KR20130083592A (ko) 2012-01-13 2013-07-23 현대약품 주식회사 치환된 피페리딘 유도체 및 이의 제조방법
EP2852685A1 (en) 2012-03-30 2015-04-01 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
KR20150030709A (ko) 2012-06-14 2015-03-20 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 췌장 내분비 세포로의 분화
CN102743770B (zh) 2012-06-18 2017-07-21 申宝忠 一种靶向性分子成像探针及活体分子成像方法
EP2892570B1 (en) 2012-09-07 2019-02-27 Bracco Imaging S.p.A Paramagnetic solid lipid nanoparticles (pslns) containing metal amphiphilic complexes for mri
WO2014124307A2 (en) 2013-02-08 2014-08-14 The Regents Of The University Of Michigan Targeted theranostics
AU2014264973B2 (en) 2013-05-06 2018-01-18 Merck Patent Gmbh Macrocycles as kinase inhibitors
US10786497B2 (en) * 2013-08-16 2020-09-29 Equip, Llc Discrete PEG constructs
WO2015038968A1 (en) 2013-09-13 2015-03-19 The General Hospital Corporation Activatable fibrin-binding probes
PL4095130T3 (pl) 2013-10-18 2024-06-10 Novartis Ag Oznaczone inhibitory specyficznego dla prostaty antygenu błonowego (psma), ich zastosowanie jako środków obrazujących i środków farmaceutycznych do leczenia raka gruczołu krokowego
US10758636B2 (en) * 2013-11-12 2020-09-01 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
EP3077009A4 (en) 2013-12-03 2017-06-14 The General Hospital Corporation Molecular imaging probes
FR3015547B1 (fr) 2013-12-20 2016-01-01 Total Sa Methode pour ajuster le taux d'inhibiteurs dans un puits de petrole ou de gaz
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
LT3129406T (lt) 2014-04-11 2019-04-10 Medimmune, Llc Konjuguoti junginiai, apimantys inžineriniu būdu sukonstruotus cisteino antikūnus
KR20160145790A (ko) 2014-04-25 2016-12-20 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
US11660357B2 (en) * 2014-05-16 2023-05-30 David A. Scheinberg One-step labeling of antibodies to high specific activity with actinium-225
US20180036442A1 (en) 2014-07-29 2018-02-08 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
BE1021191B1 (fr) 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
DE102014115154A1 (de) 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen
US10406251B2 (en) 2014-11-25 2019-09-10 Bristol-Myers Squibb Company PD-L1 binding polypeptides for imaging
WO2017120193A1 (en) * 2016-01-04 2017-07-13 University Of Kansas Drug delivery compositions and methods
WO2017161356A1 (en) 2016-03-18 2017-09-21 Wake Forest University Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography
CN118368739A (zh) * 2017-03-24 2024-07-19 中兴通讯股份有限公司 一种无线资源配置方法、装置及用户设备、网络节点
RU2019139432A (ru) 2017-05-05 2021-06-07 Сентр фор Проуб Девелопмент энд Коммерсиализэйшн Фармакокинетическая оптимизация бифункциональных хелатов и их применение
US10093741B1 (en) * 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof

Also Published As

Publication number Publication date
RU2019139432A (ru) 2021-06-07
RU2019139432A3 (pt) 2021-06-16
AU2022221451A1 (en) 2022-09-22
CN111263747A (zh) 2020-06-09
MA48861A (fr) 2020-04-01
JP2020518673A (ja) 2020-06-25
CL2019003168A1 (es) 2020-08-28
BR112019023246A2 (pt) 2020-05-19
JP2023090748A (ja) 2023-06-29
CA3062553C (en) 2024-02-06
WO2018204869A1 (en) 2018-11-08
KR20200006087A (ko) 2020-01-17
CN111263747B (zh) 2023-10-27
US20220054664A1 (en) 2022-02-24
BR112019023246B1 (pt) 2023-11-14
CA3062553A1 (en) 2018-11-08
EP3619191A4 (en) 2020-12-16
US11191854B2 (en) 2021-12-07
CN117603148A (zh) 2024-02-27
EA201992595A1 (ru) 2020-04-21
US20190030194A1 (en) 2019-01-31
AU2018261888A1 (en) 2019-11-28
KR102612882B1 (ko) 2023-12-11
ZA201908071B (en) 2023-04-26
EP3619191A1 (en) 2020-03-11
AU2018261888B2 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
BR112019023246A8 (pt) melhorias farmacocinéticas de quelatos bifuncionais e usos dos mesmos
HK1259487A1 (zh) 特定的共軛連接子，特定的免疫共軛物，製造和使用這些共軛物的方法
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
MX366503B (es) Derivados de amatoxina.
BR112015019909A2 (pt) Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112018006016A2 (pt) intermediário de ligante-droga, compostos conjugados de anticorpo-droga, composições farmacêuticas, métodos para tratar câncer, método de produção de um composto conjugado e conjugado de anticorpo-droga
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
MX2016013999A (es) Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
MX2019003938A (es) Compuestos espirociclicos.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
TN2016000472A1 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
EA202091161A1 (ru) Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
MX2017012553A (es) Compuestos espirociclicos.
MX2023008849A (es) Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico.
MX2018005232A (es) Anticuerpos anti-cd3 novedosos y sus usos.
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
BR112017028012A2 (pt) Terapia combinada com um conjugado anticorpo- fármaco anti-her2 e um inibidor de bcl-2
BR112017014229A2 (pt) conjugado, composição, e, método para tratamento de um distúrbio.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: FUSION PHARMACEUTICALS INC. (CA)

B25G Requested change of headquarter approved

Owner name: FUSION PHARMACEUTICALS INC. (CA)

B25A Requested transfer of rights approved

Owner name: CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/05/2018, OBSERVADAS AS CONDICOES LEGAIS